DDInter127 DDInter1376
Asparaginase derived from _Escherichia coli_ (L-asparagine amidohydrolase, EC 3.5.1.1) is an enzyme responsible for the metabolism of L-asparagine, by catalyzing L-asparagine into L-aspartic acid and ammonia. It also facilitates the production of oxaloacetate which is needed for general cellular metabolism. Asparaginase from _E. coli_ has clinically shown to exhibit antitumor actions in models of leukaemias [A31996, A31997]. L-asparaginase of _E. coli_ is marketed under several different trade names, including Elspar, for the treatment of acute lymphoblastic leukemia (ALL) as part of a multi-agent chemotherapeutic regimen. It is available as intramuscular or intravenous injections. Therapeutic L-asparaginase from _E. coli_ works by depleting the levels
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Asparaginase Escherichia coli {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rosuvastatin
Asparaginase Escherichia coli {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Interferon alfa-n1
Asparaginase Escherichia coli {u} may lead to a major life threatening interaction when taken with {v} Lomitapide
Asparaginase Escherichia coli {u} may lead to a major life threatening interaction when taken with {v} Etanercept
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Rosuvastatin
Asparaginase Escherichia coli may cause a moderate interaction that could exacerbate diseases when taken with Interferon alfa-n1
Asparaginase Escherichia coli may lead to a major life threatening interaction when taken with Lomitapide
Asparaginase Escherichia coli may lead to a major life threatening interaction when taken with Etanercept